Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

It’s back to school for biotech, with a packed conference schedule.

The FDA throws out the company’s second attempt at an accelerated approval.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.

A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.